Advertisement

Boston Scientific could stand to reap substantial rewards by thinking the unthinkable: Follow Johnson & Johnson's Cordis Corp. out of the coronary stents business.

Boston Scientific logo

Fifteen months ago, Cordis Corp. shocked the medical device world by pulling out of the coronary stent game, a business it helped pioneer. I wonder if its possible Boston Scientific (NYSE:BSX) could someday follow their lead.

Advertisement
Advertisement